Loading
UBR5 (E3 ubiquitin-protein ligase UBR5) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Renal cell carcinoma and 5 more.
E3 ubiquitin-protein ligase involved in different protein quality control pathways in the cytoplasm and nucleus. Mainly acts as a ubiquitin chain elongator that extends pre-ubiquitinated substrates. Component of the N-end rule pathway: ubiquitinates proteins bearing specific N-terminal residues that are destabilising according to the N-end rule, leading to their degradation.
CIViC holds 1 clinical evidence item and 0 assertions across 1 variant. Open Targets scores its association with cancer at 0.70 (direct and indirect evidence; datatypes literature 0.98, genetic association 0.27, somatic mutation 0.88). IntOGen calls it a driver in 7 cohorts (2 activating, 5 loss-of-function), covering Acute Myeloid Leukaemia, Invasive Breast Carcinoma, Chromophobe Renal Cell Carcinoma, Cutaneous Squamous Cell Carcinoma, Melanoma, Stomach Adenocarcinoma.
In plain words · UBR5 (E3 ubiquitin-protein ligase UBR5) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Renal cell carcinoma and 5 more.
UBR5 (E3 ubiquitin-protein ligase UBR5) is an enzyme. The public catalogues list it as an oncogene driver, a tumour suppressor, a biomarker and a DNA repair gene, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Gastric & gastro-oesophageal junction cancer, Breast cancer, Renal cell carcinoma and 5 more.
E3 ubiquitin-protein ligase involved in different protein quality control pathways in the cytoplasm and nucleus. Mainly acts as a ubiquitin chain elongator that extends pre-ubiquitinated substrates.
No product in this corpus aims at UBR5 yet. Inhibitors are shaped to fit the enzyme's active site so the reaction the cancer relies on stops.
Tumour-specific alteration: the catalogues call it an oncogene driver (IntOGen cohort analysis finds it activated more often than chance) and a tumour suppressor (IntOGen finds it knocked out more often than chance), so the direction differs between cohorts but the alteration is somatic either way; what a medicine would aim at or exploit is the altered form or its loss, absent from normal cells; no corpus medicine is aimed at it yet. HPA UBR5: RNA low tissue specificity; no normal tissue stained high. Distribution: 7 cancer families in the corpus carry a prevalence row, label threshold or catalogue link for it (Gastric & gastro-oesophageal junction cancer, Breast cancer (all types), Renal cell carcinoma, Skin cancer (all types), Colorectal cancer, Lymphoma, Ovarian cancer); Open Targets associates it with 0 specific cancer types at or above 0.5. (Rule 6 of scripts/fetch-target-specificity.ts.)
Sources: UniProt O95071; CIViC gene UBR5; IntOGen UBR5; Human Protein Atlas UBR5 tissue; Open Targets ENSG00000104517 associations
First described 1998. Earliest sequence paper UniProt cites for the protein: Callaghan M.J. et al, Oncogene, 1998, "Identification of a human HECT family protein with homology to the Drosophila tumor suppressor gene hyperplastic discs". Source.
Sources: HGNC HGNC:16806 (approved symbol, name, aliases, locus and cross-references (hgnc_complete_set.txt)); UniProt O95071 (protein name, function text, keywords and locations (REST API)); CIViC gene UBR5 (1 evidence items, 0 assertions, 1 variants; diseases: Mantle Cell Lymphoma (GraphQL API, CC0)); Open Targets ENSG00000104517 (association with cancer (MONDO_0004992) 0.70; per-cancer scores at or above 0.5: colorectal cancer 0.55, gastric cancer 0.57, ovarian cancer 0.51, melanoma 0.59, non-Hodgkin lymphoma 0.52, skin cancer 0.57 (GraphQL API, CC0)); IntOGen UBR5 (driver in 7 cohorts (Act 2, LoF 5); Compendium_Cancer_Genes.tsv release 20240920, CC0 1.0)
E3 ubiquitin-protein ligase involved in different protein quality control pathways in the cytoplasm and nucleus. Mainly acts as a ubiquitin chain elongator that extends pre-ubiquitinated substrates. Component of the N-end rule pathway: ubiquitinates proteins bearing specific N-terminal residues that are destabilising according to the N-end rule, leading to their degradation. Recognises type-1 N-degrons, containing positively charged amino acids (Arg, Lys and His). Together with UBR4, part of a cytoplasm protein quality control pathway that prevents protein aggregation by catalysing assembly of heterotypic 'Lys-11'-/'Lys-48'-linked branched ubiquitin chains on aggregated proteins, leading to substrate recognition by the segregase p97/VCP and degradation by the proteasome: UBR5 is probably branching multiple 'Lys-48'-linked chains of substrates initially modified with mixed conjugates by UBR4. Together with ITCH, catalyses 'Lys-48'-/'Lys-63'-branched ubiquitination of TXNIP, leading to its degradation: UBR5 mediates branching of 'Lys-48'-linked chains of substrates initially modified with 'Lys-63'-linked conjugates by ITCH. Location: Nucleus; Cytoplasm (UniProt). Locus 8q22.3 (HGNC).
RNA: low tissue specificity, detected in all normal tissues.
No normal tissue stained high.
No cancer sample stained medium or high.
Human Protein Atlas version 25.1, antibody staining at reliability approved, enhanced or supported; used under CC BY-SA 3.0. Staining counts are patients per level in the atlas cohort, not population prevalence.
Query for this target: (TITLE:"UBR5" OR ABSTRACT:"UBR5" OR TITLE:"ubiquitin protein ligase E3 component n-recognin 5" OR ABSTRACT:"ubiquitin protein ligase E3 component n-recognin 5" OR TITLE:"E3 ubiquitin-protein ligase UBR5" OR ABSTRACT:"E3 ubiquitin-protein ligase UBR5" OR TITLE:"DD5" OR ABSTRACT:"DD5" OR TITLE:"KIAA0896" OR ABSTRACT:"KIAA0896" OR TITLE:"EDD1" OR ABSTRACT:"EDD1") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about UBR5, not a curated reading list.